FY2025 EPS Estimates for Penumbra Boosted by William Blair

Penumbra, Inc. (NYSE:PEN) – William Blair increased their FY2025 earnings per share estimates for Penumbra in a research note issued on Thursday, November 6th. William Blair analyst B. Vazquez now expects that the company will post earnings of $3.90 per share for the year, up from their prior estimate of $3.68. William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for Penumbra’s current full-year earnings is $3.67 per share. William Blair also issued estimates for Penumbra’s Q4 2025 earnings at $1.24 EPS, Q1 2026 earnings at $1.11 EPS, Q2 2026 earnings at $1.20 EPS, Q3 2026 earnings at $1.23 EPS, Q4 2026 earnings at $1.54 EPS, FY2026 earnings at $5.07 EPS, Q1 2027 earnings at $1.49 EPS, Q2 2027 earnings at $1.59 EPS, Q3 2027 earnings at $1.55 EPS and FY2027 earnings at $6.55 EPS.

Other analysts also recently issued reports about the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $326.00 price objective on shares of Penumbra in a report on Monday, October 27th. Morgan Stanley boosted their target price on shares of Penumbra from $260.00 to $266.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 31st. Wall Street Zen cut shares of Penumbra from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Royal Bank Of Canada lowered their price target on Penumbra from $330.00 to $325.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 30th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Penumbra in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Penumbra currently has an average rating of “Moderate Buy” and an average price target of $305.69.

Penumbra Price Performance

NYSE PEN opened at $266.25 on Friday. Penumbra has a fifty-two week low of $221.26 and a fifty-two week high of $310.00. The stock’s 50-day moving average is $255.94 and its two-hundred day moving average is $258.62. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.75 and a quick ratio of 4.04. The firm has a market cap of $10.38 billion, a P/E ratio of 70.81, a price-to-earnings-growth ratio of 2.10 and a beta of 0.51.

Penumbra (NYSE:PEN) last issued its earnings results on Wednesday, November 5th. The company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.07. Penumbra had a return on equity of 11.55% and a net margin of 11.54%.The firm had revenue of $354.69 million for the quarter, compared to the consensus estimate of $340.77 million. During the same quarter in the previous year, the company posted $0.85 earnings per share. The business’s quarterly revenue was up 17.8% compared to the same quarter last year. Penumbra has set its FY 2025 guidance at EPS.

Insider Activity at Penumbra

In other news, Director Thomas Wilder sold 186 shares of the company’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $253.93, for a total value of $47,230.98. Following the sale, the director directly owned 186 shares in the company, valued at approximately $47,230.98. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Johanna Roberts sold 600 shares of the stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $249.70, for a total value of $149,820.00. Following the completion of the transaction, the executive vice president directly owned 64,257 shares of the company’s stock, valued at approximately $16,044,972.90. The trade was a 0.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 48,802 shares of company stock valued at $12,588,928. Corporate insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Concurrent Investment Advisors LLC acquired a new stake in shares of Penumbra during the 1st quarter worth about $259,000. Envestnet Asset Management Inc. grew its stake in Penumbra by 1.7% during the first quarter. Envestnet Asset Management Inc. now owns 61,499 shares of the company’s stock worth $16,445,000 after buying an additional 1,014 shares during the last quarter. Crossmark Global Holdings Inc. increased its holdings in shares of Penumbra by 13.1% during the first quarter. Crossmark Global Holdings Inc. now owns 2,844 shares of the company’s stock worth $761,000 after buying an additional 330 shares in the last quarter. Cerity Partners LLC increased its holdings in shares of Penumbra by 36.7% during the first quarter. Cerity Partners LLC now owns 8,201 shares of the company’s stock worth $2,193,000 after buying an additional 2,202 shares in the last quarter. Finally, State of Michigan Retirement System raised its stake in shares of Penumbra by 1.1% in the first quarter. State of Michigan Retirement System now owns 9,214 shares of the company’s stock valued at $2,464,000 after acquiring an additional 100 shares during the last quarter. 88.88% of the stock is owned by institutional investors.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.